Comparison of the Effects of Highintensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: We compared the effects of high-intensity statin monotherapy versus moderateintensity statin and ezetimibe combination therapy on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). Methods: Using the Korean National Health Insurance Service database, we screened 82,941 patients with AMI who underwent percutaneous coronary intervention (PCI) between 2013 and 2016. Among them, we identified 9,908 patients treated with atorvastatin 40 mg (A40, n=4,041), atorvastatin 20 mg + ezetimibe 10 mg (A20+E10, n=233), rosuvastatin 20 mg (R20, n=5,251), or rosuvastatin 10 mg + ezetimibe 10 mg (R10+E10, n=383). The primary outcome was MACE, a composite of all-cause death, non-fatal myocardial infarction undergoing PCI, repeat revascularization, and ischemic stroke. Multivariable analyses were performed using the inverse probability of treatment weighting method. Results: The incidence rate of MACE in the overall population was 42.97 cases per 1,000 person-years. There was no significant difference in the risk of composite outcomes of MACE between the groups. However, the R10+E10 group showed a higher risk of all-cause death (hazard ratio, 2.07; 95% confidence interval, 1.08–3.94) than the A40 group (reference group) in the weighted multivariable model. Conclusions: In this study, there was no significant difference in the composite outcome of MACE between high-intensity statin monotherapy and moderate-intensity statin and ezetimibe combination therapy.
Abstract
Objective: We compared the effects of high-intensity statin monotherapy versus moderateintensity statin and ezetimibe combination therapy on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). Methods: Using the Korean National Health Insurance Service database, we screened 82,941 patients with AMI who underwent percutaneous coronary intervention (PCI) between 2013 and 2016. Among them, we identified 9,908 patients treated with atorvastatin 40 mg (A40, n=4,041), atorvastatin 20 mg + ezetimibe 10 mg (A20+E10, n=233), rosuvastatin 20 mg (R20, n=5,251), or rosuvastatin 10 mg + ezetimibe 10 mg (R10+E10, n=383). The primary outcome was MACE, a composite of all-cause death, non-fatal myocardial infarction undergoing PCI, repeat revascularization, and ischemic stroke. Multivariable analyses were performed using the inverse probability of treatment weighting method. Results: The incidence rate of MACE in the overall population was 42.97 cases per 1,000 person-years. There was no significant difference in the risk of composite outcomes of MACE between the groups. However, the R10+E10 group showed a higher risk of all-cause death (hazard ratio, 2.07; 95% confidence interval, 1.08–3.94) than the A40 group (reference group) in the weighted multivariable model. Conclusions: In this study, there was no significant difference in the composite outcome of MACE between high-intensity statin monotherapy and moderate-intensity statin and ezetimibe combination therapy.
참고문헌 (23)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
- Cholesterol Treatment Trialists'(CTT)Collaboration, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Waters DD, "Lipid treatment assessment project 2 : a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals", Circulation, 120, pp.28~34 (2009)
- Dujovne CA, "What combination therapy with a statin, if any, would you recommend?", Curr Atheroscler Rep, 13, pp.12~22 (2011)
- Knopp RH, "Drug treatment of lipid disorders", N Engl J Med, 341, pp.498~511 (1999)
- Stein E, "Results of phase I", II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor, 2001, pp.3, E11~
- Stroes ES, "Statin-associated muscle symptoms : impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management", Eur Heart J, 36, pp.1012~1022 (2015)
- Mach F, "Adverse effects of statin therapy : perception vs. the evidence-focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract", Eur Heart J, 39, pp.2526~2539 (2018)
- Davidson MH, "Ezetimibe : a novel option for lowering cholesterol", Expert Rev Cardiovasc Ther, 1, pp.11~21 (2003)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Bays HE, "Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia", Am J Cardiol, 112, pp.1885~1895 (2013)
- Leiter LA, "Efficacy and safety of ezetimibe added on to atorvastatin(40 mg)compared with uptitration of atorvastatin(to 80 mg)in hypercholesterolemic patients at high risk of coronary heart disease", Am J Cardiol, 102, pp.1495~1501 (2008)
- Wu NQ, "Comparison of statin plus ezetimibe with doubledose statin on lipid profiles and inflammation markers", Lipids Health Dis, 17, pp.265~ (2018)
- Ai C, "Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids : a systematic review and meta-analyse", Lipids Health Dis, 17, pp.239~ (2018)
- Pauriah M, "High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction : a population-based study", Heart, 100, pp.867~872 (2014)
- Ji MS, "Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis", Int J Cardiol, 225, pp.50~59 (2016)
- Quan H, "Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6countries", Am J Epidemiol, 173, pp.676~682 (2011)
- Oesterle A, "Pleiotropic effects of statins on the cardiovascular system", Circ Res, 120, pp.229~243 (2017)
- Ray KK, "The potential relevance of the multiple lipid-independent(pleiotropic)effects of statins in the management of acute coronary syndromes", J Am Coll Cardiol, 46, pp.1425~1433 (2005)
- Kim J, "High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention", J Am Heart Assoc, 7, pp.e009517~ (2018)
- de Waha S, "Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : an individual patient data pooled analysis from seven randomized trials", Eur Heart J, 38, pp.3502~3510 (2017)
- Kim JS, "Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction : the STATIN STEMI trial", JACC Cardiovasc Interv, 3, pp.332~339 (2010)